Global Progressive Multifocal Leukoencephalopathy Treatment Market, By Type (Antiretroviral Therapy, Anti JCV and Asymptomatic), Treatment (Medication, Therapies), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Progressive Multifocal Leukoencephalopathy Treatment Market Analysis and Size
Progressive Multifocal Leukoencephalopathy occurs in roughly 1 in 200,000 people. There is no known cure for this disease, but treatment can help to improve symptoms. PML is mostly reported in cancer patients on chronic immunosuppressive medications or those suffering from AIDS. Developing treatment options such as anti-retroviral and antivirals are projected to create substantial growth opportunities for several new players entering the progressive multifocal leukoencephalopathy treatment market.
Data Bridge Market Research analyses a growth rate in the progressive multifocal leukoencephalopathy treatment market in the forecast period 2023-2030. The expected CAGR of progressive multifocal leukoencephalopathy treatment market is tend to be around 16.4% in the mentioned forecast period. The market was valued at USD 1279.15 million in 2022, and it would grow upto USD 4310.68 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Progressive Multifocal Leukoencephalopathy Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Antiretroviral Therapy, Anti JCV and Asymptomatic), Treatment (Medication, Therapies), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Ipsen Pharma (France), Spectrum Pharmaceuticals, Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan), Dr. Reddy’s Laboratories Ltd. (India), Apotex Inc. (Canada), F. Hoffman-La Roche Ltd. (Switzerland), Lilly (U.S.), Merck & Co., Inc. (U.S.), Mylan N.V (U.S.), AbbVie, Inc (U.S.), Bristol-Myers Squibb Company (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Progressive multifocal leukoencephalopathy is a kind of neurological condition characterized by cell destruction that produces myelin. Myelin is a sticky material that supports nerve cells, in the brain and spinal cord, also known as white matter of the central nervous system. In healthy individuals, the JCV virus remains inactive and leads to this dreadful disease only when the immune system is seriously compromised. Major symptoms include problems with vision, balance, coordination, speech, and thinking.
Global Progressive Multifocal Leukoencephalopathy Treatment Market Dynamics
Drivers
- Increasing demand of anti-retroviral therapy
The increasing demand of anti-retroviral therapy for these patients help in the growth of the market. Anti-Retroviral Therapy is a type of progressive multifocal leukoencephalopathy treatment, which helps to stop the replication of HIV in the body. It is generally prescribed for people infected with HIV. This therapy helps maintain the person's health by decreasing the amount of HIV in their blood. It also helps in the prevention of AIDS.
- Rising R&D activities by several market players
Increasing emphasis on the R&D of drugs and therapies for rare disease creates a huge opportunity for the market. Numerous companies are trying to scrutinise innovative therapies aimed at control of JC virus infection instead of improving immunity that is expected to increase the growth of the progressive multifocal leukoencephalopathy treatment market during the forecast period.
Opportunities
- Growing adoption of drug stores
Drug Stores are the major users of PML treatment drugs. These stores provide prescription and over-the-counter medications and other health and personal care items to consumers. The use of PML therapeutics in drug stores is mainly for HIV patients who require lifelong treatment. Drug stores offer convenience to these treatment users, who can buy the treatment from these drug stores in their nearby areas.
- High-end Use of Anti-JCV drugs
Anti-JCV drugs are used to treat PML extensively. They work by decreasing the amount of virus in the body, which may help improve symptoms. These drugs come as pills that can be taken orally. Some common antiviral/anti-JCV drugs include entecavir (Baraclude) and tenofovir (Viread). Thus, this serves as a major treatment option for these patients.
Restraints/Challenges
- Lack of treatment options
Lack of specific treatments and therapies for progressive multifocal leukoencephalopathy treatment which do not lead to favourable outcomes is likely to hamper the market growth. The current progressive multifocal leukoencephalopathy treatment options focus on immune reconstitution, restoration of immune responses to JC virus infection, and eventual suppression of immune reconstitution inflammatory syndrome. Thus, specified treatment options that help the patients' exact improvement are necessary.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. Many times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health.
This progressive multifocal leukoencephalopathy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the progressive multifocal leukoencephalopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Progressive Multifocal Leukoencephalopathy Treatment Market Scope
The progressive multifocal leukoencephalopathy treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Antiretroviral Therapy
- Anti JCV
- Asymptomatic
Treatment
- Medication
- Therapies
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Progressive Multifocal Leukoencephalopathy Treatment Market Regional Analysis/Insights
The progressive multifocal leukoencephalopathy treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the progressive multifocal leukoencephalopathy treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the presence of the primary manufacturers, high spending on research and development and health care and qualified professionals.
Asia-Pacific dominates the market due to an increased prevalence of HIV infection and progressive multifocal leukoencephalopathy, especially in the Chinese and Indian regions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Progressive Multifocal Leukoencephalopathy Treatment Market Share Analysis
The progressive multifocal leukoencephalopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to progressive multifocal leukoencephalopathy treatment market.
Key players operating in the progressive multifocal leukoencephalopathy treatment market include:
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Ipsen Pharma (France)
- Spectrum Pharmaceuticals, Inc. (U.S.)
- Takeda Pharmaceutical Company Limited. (Japan)
- Dr. Reddy’s Laboratories Ltd. (India)
- Apotex Inc. (Canada)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Mylan N.V (U.S.)
- AbbVie, Inc (U.S.)
- Bristol-Myers Squibb Company (U.S.)
SKU-